Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
New England Journal of Medicine · 25.01.2024 · 390 (4) · 301-313
DOI: 10.1056/nejmoa2312054 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 25.01.2024. Verfasst von Pieter Sonneveld und 43 weiteren Autor:innen. Beteiligte Einrichtung: From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Univ…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Multiple Myeloma. Die Arbeit wurde bisher 631-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: European Myeloma Network in collaboration with Janssen Research & Development, LLC.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of…
ORCID-Profile: Tobias Silzle
Förderung
- European Myeloma Network in collaboration with Janssen Research & Development, LLC
Zitieren
APA
Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., Perrot, A., Cavo, M., Belotti, A., Broijl, A., Gay, F., Mina, R., Nijhof, I. S., van de Donk, N. W. C. J., Katodritou, E., …, & PERSEUS Trial Investigators (2024). Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 390(4), 301-313. https://doi.org/10.1056/nejmoa2312054
Vancouver
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine. 2024;390(4):301-313. doi:10.1056/nejmoa2312054
BibTeX
@article{Sonneveld2024,
author = {Sonneveld, Pieter and Dimopoulos, Meletios A and Boccadoro, Mario and Quach, Hang and Ho, P Joy and Beksac, Meral and Hulin, Cyrille and Antonioli, Elisabetta and Leleu, Xavier and Mangiacavalli, Silvia and Perrot, Aurore and Cavo, Michele and Belotti, Angelo and Broijl, Annemiek and Gay, Francesca and Mina, Roberto and Nijhof, Inger S and van de Donk, Niels W C J and Katodritou, Eirini and Schjesvold, Fredrik and Sureda Balari, Anna and Rosiñol, Laura and Delforge, Michel and Roeloffzen, Wilfried and Silzle, Tobias and Vangsted, Annette and Einsele, Hermann and Spencer, Andrew and Hajek, Roman and Jurczyszyn, Artur and Lonergan, Sarah and Ahmadi, Tahamtan and Liu, Yanfang and Wang, Jianping and Vieyra, Diego and van Brummelen, Emilie M J and Vanquickelberghe, Veronique and Sitthi-Amorn, Anna and de Boer, Carla J and Carson, Robin and Rodriguez-Otero, Paula and Bladé, Joan and Moreau, Philippe and PERSEUS Trial Investigators, PERSEUS Trial Investigators},
title = {Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma},
journal = {New England Journal of Medicine},
year = {2024},
volume = {390},
number = {4},
pages = {301--313},
doi = {10.1056/nejmoa2312054}
}
EUVIMED